Skip to main content
SpringerLink
Log in

ITIH4: Effective Serum Marker, Early Warning and Diagnosis, Hepatocellular Carcinoma

  • Original Article
  • Published:
Pathology & Oncology Research

Abstract

Hepatocellular carcinoma (HCC) is a highly lethal malignant tumor evolved from cirrhosis. It is quite significant to seek accurate, easy markers for early warning and diagnosis of HCC. Through prospective cohort follow-up study and mass spectrometry, we discovered and verified a serum marker valuable for early warning and diagnosis. Follow-up observation was performed on cirrhosis patients. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) was adopted to detect the serums of patients, and the serum polypeptides with a potential value in early HCC warning and diagnosis were screened. Electrospray ionization quadrupole time-of-flight tandem mass spectrometry (ESI-Q-TOF-MS/MS) was exploited to identify these screened polypeptides. Moreover, the serum marker concentration was determined by ELISA to validate the clinical value of the serum marker. Among 109 cirrhosis patients followed up for two years, 29 patients (26.6%) finally progressed into HCC. MALDI-TOF MS shows that the concentration of a 3155.66Da polypeptide was significantly different between the patients that progressed into HCC and those not. Through MS/MS identification, it is confirmed that the polypeptide is inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4). The serum ITIH4 concentrations in two groups were measured with ELISA and compared with Alpha-fetoprotein (AFP). Results show that serum ITIH4 and AFP concentrations were negatively correlated (r=−0.263, p=0.0006), and the ITIH4 concentration had a significant intergroup difference (p=0.000). Receiver operating characteristic (ROC) curve indicates that its predictive value (area under the curve, AUC) is 0.667, superior to AFP. For the patients progressing into HCC, serum samples were separately collected when they were recruited and diagnosed as cirrhosis. Measurement on these samples reveals that ITIH4 was declining during the progression of HCC (p=0.006). By virtue of mass spectrometry, we discovered and identified a biomarker valuable for early HCC warning and diagnosis. This marker overperforms the commonly used AFP, demonstrating a bright prospect.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Ervik M (2013) Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. IARC CancerBase. http://globocan.iarc.fr

    Google Scholar 

  2. Liovet JM, Burroughs A, Bruix J, BCLC, Liver Unitet, Digestive Disease Institute, IDIBAPS et al (2003) Hepatocellular carcinoma. Lancet 362:1907–1917

    Article  Google Scholar 

  3. Zhang Z, Zhang Y, Wang Y, Xu L, Xu W (2015) Alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma. Onco Targets Ther 31(9):123–129

    CAS  Google Scholar 

  4. Jordi B, Morris S (2011) Management of hepatocellular carcinoma: an update. Hepatol 53:1020–1022

    Article  Google Scholar 

  5. Guidelines for diagnosis and treatment of primary hepatocellular carcinoma (2011) Chin Clin Oncol 16:929–946

  6. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30

    Article  PubMed  Google Scholar 

  7. Virginia HG, Fanny T (2013) Management of small hepatocellular carcinoma in cirrhosis: focus on portal hypertension. World J Gastroenterol 19:1193–1199

    Article  Google Scholar 

  8. Zhao Y, Wang M, Cui C, Zhang L, Liao F, Li H (2015) Significance of combined tests of serum golgi glycoprotein 73 and other biomarkers in diagnosis of small primary hepatocellular carcinoma. Cancer Biomark. 15:677–683

    Article  PubMed  CAS  Google Scholar 

  9. Bao YX, Yang Y, Zhao HR, Mao R, Xiao L, Zhang YF (2013) Clinical significance and diagnostic value of Golgi-protein 73 in patients with early-stage primary hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi. 35:505–508

    PubMed  CAS  Google Scholar 

  10. Witjes CD, van Aalten SM, Steyerberg EW, Borsboom GJ, de Man RA, Verhoef C, Ijzermans JN (2013) Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int. 7:59–64

    Article  PubMed  Google Scholar 

  11. Taneja S, Ahmad I, Sen S, Kumar S, Arora R, Gupta VK, Aggarwal R et al (2011) Plasma pep tidome profiling of acute hepatitis E patients by MALDI-TOF/TOF. Proteome Sci 9:5

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Wang J, Wang X, Lin S, Chen C, Wang C, Ma Q, Jiang B et al (2013) Identification of kininogen-1 as a serum biomarker for the early detection of advanced colorectal adenoma and colorectal cancer. PLoS One 8:e70519

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Huijbers A, Velstra B, Dekker TJ, Mesker WE, van der Burgt YE, Mertens BJ, Deelder AM et al (2010) Proteomic serum biomarkers and their potential application in cancer screening programs. Int J Mol Sci 11:4175–4193

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Cobo F (2013) Application of maldi-tof mass spectrometry in clinical virology: a review. Open. Virol J 27:84–90

    Google Scholar 

  15. Qiu F, Gao YH, Jiang CG, Tian YP, Zhang XJ (2010) Serum proteomic profile analysis for endometrial carcinoma detection with MALDI-TOF MS. Arch Med Sci 6:245–252

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. TTang Y, Kitisin K, Jogunoori W, Li C, Deng C, Mueller SC, Ressom HW et al (2008) Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci U S A 105:2445–2450

    Article  Google Scholar 

  17. Bhanumathy CD, Tang Y, Monga SPS, Katuri V, Cox JA, Mishra B, Mishra L et al (2002) Itih-4, a serine protease inhibitor regulated in interleukin-6-dependent liver formation: role in liver development and regeneration. Dev Dyn 223:59–69

    Article  PubMed  CAS  Google Scholar 

  18. The guidelines of prevention and treatment for chronic hepatitis B (2010 version) (2011) Chinese journal of experimental and clinical infectious disease (Electronic Version) 5:79–100

  19. Guideline of prevention and treatment of hepatitis C (2004) Zhonghua Yu Fang Yi Xue Za Zhi 38:210–215

  20. Daniele B, Bencivenga A, Megna AS (2004) Alpha fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 127:S108–S112

    Article  PubMed  Google Scholar 

  21. Yang J, Yang SY, Hu XY, Huo SF, Shang WL, Li ZF, Lei N et al (2010) Serum peptidome profiling in patients with lung cancer. Anat Rec (Hoboken) 293:2027–2033

    Article  CAS  Google Scholar 

  22. Li J, Jin H, Li L, Shang L, Zhao Y, Wei F et al (2012) Detection of murine toxoplasmosis using magnetic bead-based serum peptide profiling by MALDI-TOF MS. Vector Borne Zoonotic Dis 12:462–466

    Article  PubMed  PubMed Central  Google Scholar 

  23. Yang J, Gao Y, Zhao LY, Liu LY, Qin YN, Wang XE, Liu Y et al (2014) Identification of potential serum proteomic biomarkers for clear cell renal cell carcinoma. PLoS One 9:e111364

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Orvisky E, Drake SK, Martin BM, Abdel-Hamid M, Ressom HW, Varghese RS et al (2006) Enrichment of low molecular weight fraction of serum for ms analysis of peptid enrichment of low molecular weight fraction of serum for ms analysis of peptides associated with hepatocellular carcinoma. Proteomics 6:2895–2902

    Article  PubMed  CAS  Google Scholar 

  25. Schwegler EE, Cazares L, Steel LF, Adam BL, Johnson DA, Semmes OJ, Block TM et al (2005) SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 41:634–642

    Article  PubMed  Google Scholar 

  26. Tian L, Wang Y, Xu DB, Gao YH, Wen XY, Tian YP (2014) The differential diagnostic model for serous peptidomics in HBV carriers established by MALDI-TOF-MS analysis. Clin Biochem 47:56–62

    Article  PubMed  CAS  Google Scholar 

  27. Noguchi Y, Kurokawa MS, Okuse C, Matsumoto N, Nagai K, Sato T, Arito M et al (2013) Serum peptides, represented by complement 3f des-arginine, are useful for prediction of the response to pegylated interferon-α plus ribavirin in patients with chronic hepatitis C. Hepatol Res 43:743–756

    Article  PubMed  CAS  Google Scholar 

  28. Ivancic MM, Irving AA, Jonakin KG, Dove WF, Sussman MF (2014) The concentrations of EGFR, LRG1, ITIH4, and F5 in serum correlate with the number of colonic adenomas in ApcPirc/+ rats. Cancer Prev Res (Phila) 7:1160–1169

    Article  CAS  Google Scholar 

  29. Subbannayya Y, Mir SA, Renuse S (2012) Identification of differentially expressed serum proteins in gastric adenocarcinoma. J Proteome 127:80–88

    Article  CAS  Google Scholar 

  30. Yang J, Xiong X, Liu S (2015) Identification of novel serum peptides biomarkers for female breast cancer patients in Western China. Proteomics 12:doi: 10.1002/pmic.201500321

  31. Gangadharan B, Antrobus R, Dwek RA, Zitzmann N (2007) Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem 53:1792–1799

    Article  PubMed  CAS  Google Scholar 

  32. Noh CK, Kim SS, Kim DK, Lee HY, Cho HJ, Yoon SY, Hyun SA et al (2014) Inter-alpha-trypsin inhibitor heavy chain H4 as a diagnostic and prognostic indicator in patients with hepatitis B virus-associated hepatocellular carcinoma. Clin Biochem 47:1257–1261

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the Capital Medical Development Project of China (2014-2-5031).

Author information

Authors and Affiliations

  1. Graduate Student Team, Medical University of PLA, Beijing, China

    Xiaohan Li, Bo Li, Boan Li, Tongsheng Guo, Zhiqiang Sun, Xiaoxi Li, Lin Chen, Weijiao Chen, Peng Chen & Yuanli Mao

  2. China Center for Clinical Laboratory, 302 Hospital of PLA, Beijing, China

    Xiaohan Li & Yuanli Mao

  3. Beijing University of Technology, 100 Pingleyuan, Chaoyang District, China

    Yanjun Zeng

Authors
  1. Xiaohan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bo Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Boan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tongsheng Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhiqiang Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiaoxi Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lin Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Weijiao Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Peng Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yuanli Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yanjun Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yuanli Mao or Yanjun Zeng.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, X., Li, B., Li, B. et al. ITIH4: Effective Serum Marker, Early Warning and Diagnosis, Hepatocellular Carcinoma. Pathol. Oncol. Res. 24, 663–670 (2018). https://doi.org/10.1007/s12253-017-0285-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-017-0285-4

Keywords

Search

Navigation